Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLP dosing regimens in healthy volunteers
NCT02079233Phase 1Completed
- Sponsor
- Sorbent Therapeutics
- Start
- May 2010
- Primary completion
- Jul 2010
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of CLP-1001 in heart failure (HF) and chronic kidney disease (CKD) (4 arms), sponsored by Sorbent Therapeutics. Primary endpoint: Change in fecal sodium content. Started May 2010; status: completed.
02
Drugs
CLP-1001
03
Conditions
heart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02079233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02079233.